Lytix Biopharma AS Total Liabilities

Latest as of December 2025: Nkr19.77 Million NOK ≈ $2.08 Million USD

Lytix Biopharma AS total liabilities. Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has total liabilities worth Nkr19.77 Million NOK (≈ $2.08 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LYTIX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Lytix Biopharma AS (2017–2025)

Total liabilities of Lytix Biopharma AS from 2017 to 2025. This chart illustrates how Lytix Biopharma AS's total liabilities have evolved over time, based on quarterly financial data.

Lytix Biopharma AS Competitors by Total Liabilities

The table below lists competitors of Lytix Biopharma AS ranked by their total liabilities.

Company	Country	Total Liabilities
Metro Systems Corporation Public Company Limited BK:MSC	Thailand	฿2.08 Billion
Taiwan Wax Co Ltd TWO:1742	Taiwan	NT$174.60 Million
GAMING INNOVATION DL 1 F:GI11	Germany	€174.54 Million
CHANJET INFO.TECHN.-H-YC1 F:C7D	Germany	€936.82 Million
Great Elm Group Inc NASDAQ:GEG	USA	$72.88 Million
Thorney Opportunities Ltd AU:TOP	Australia	AU$24.49 Million
Korea Flange KO:010100	Korea	₩611.10 Billion
ADVENICA AB F:65R	Germany	€93.48 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Lytix Biopharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LYTIX total asset value.

Liquidity & Leverage Metrics

Lytix Biopharma AS Total Liabilities Ratios Explained

Lytix Biopharma AS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	4.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.57	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lytix Biopharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lytix Biopharma AS (2017–2025)

The table below shows the annual total liabilities of Lytix Biopharma AS from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	Nkr19.77 Million ≈ $2.08 Million	-48.83%
2024-12-31	Nkr38.64 Million ≈ $4.07 Million	+207.77%
2023-12-31	Nkr12.55 Million ≈ $1.32 Million	-25.67%
2022-12-31	Nkr16.89 Million ≈ $1.78 Million	+26.64%
2021-12-31	Nkr13.34 Million ≈ $1.40 Million	+4.79%
2020-12-31	Nkr12.73 Million ≈ $1.34 Million	+230.25%
2019-12-31	Nkr3.85 Million ≈ $405.55K	-78.41%
2018-12-31	Nkr17.85 Million ≈ $1.88 Million	-49.44%
2017-12-31	Nkr35.30 Million ≈ $3.71 Million	--

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$63.93 Million

Nkr607.51 Million NOK

Market Cap Rank

#20775 Global

#189 in Norway

Share Price

Nkr7.90

Change (1 day)

+2.07%

52-Week Range

Nkr7.50 - Nkr11.50

All Time High

Nkr18.60